A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

BACKGROUND: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treatments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. We have developed a humanized monoclonal antibody YS110 against CD26 expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Mutsumi, Madokoro, Hiroko, Yamada, Koji, Nishida, Hiroko, Morimoto, Chikao, Sakamoto, Michiie, Yamada, Taketo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851800/
https://www.ncbi.nlm.nih.gov/pubmed/27134571
http://dx.doi.org/10.1186/s12935-016-0310-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851800/
https://www.ncbi.nlm.nih.gov/pubmed/27134571
http://dx.doi.org/10.1186/s12935-016-0310-9

Ejemplares similares